| Literature DB >> 35954673 |
Marcin Bakalarz1, Jacek J Rożniecki2, Mariusz Stasiołek3.
Abstract
Vertebral artery hypoplasia (VAH) belongs to the relatively frequent Doppler ultrasonography (US) findings. However, its clinical significance remains controversial. This was a retrospective study analyzing clinical data of patients undergoing US because of cerebrovascular disease in a single academic neurology center. In the dataset of 2500 US examinations, 80 individuals with VAH (VA diameter < 2.0 mm) were identified (3.2% of all patients). Patients with significant vertebral artery asymmetry (SVAA, difference in VA diameters > 1.0 mm) (n = 80) and patients with normal VA diameter (n = 80) were also recruited. Clinical parameters including clinical signs and symptoms, concomitant diseases, imaging findings and the hospitalization outcome were compared between groups. The frequency of vertigo was highest in VAH group. Ischemic lesions of the cerebellum were found in 10% of VAH patients, 16% of SVAA patients and 5% of control subjects. Neurological deficits improved in over 60% of patients in each group, whereas ca. 30% of patients remained in a stable neurological status. The percentage of patients who deteriorated did not exceed 5% in any of the groups. The results of our study support a relatively high frequency of VAH. Our observations suggest coexistence of VAH with a higher frequency of neurological presentations associated with posterior arterial circulation of the central nervous system.Entities:
Keywords: cerebrovascular disease; ischemic stroke; vertebral artery hypoplasia
Mesh:
Year: 2022 PMID: 35954673 PMCID: PMC9368006 DOI: 10.3390/ijerph19159317
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Comparison of the size of vertebral arteries: at the bottom-typical vertebral artery with the diameter 4.3 mm, at the top-hypoplastic vertebral artery with the diameter of 1.8 mm.
Gender structure.
| Gender | VAH | SVAA | Control |
| |||
|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | ||
| Female | 46 | 57.5% | 43 | 53.8% | 47 | 58.8% | 0.802 |
| Male | 34 | 42.5% | 37 | 46.3% | 33 | 41.3% | |
Median age of patients.
| VAH | SVAA (Q1, Q3) | Control (Q1, Q3) |
| |
|---|---|---|---|---|
| Age | 65.0 (52.8–72.0) | 67.0 (57.0–72.3) | 67.0 (58.0–79.0) | 0.352 |
Frequency of neurological symptoms.
| Neurological Symptoms | VAH | SVAA | Control Group |
| |||
|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | ||
| Limb paresis | 38 | 47.5% | 44 | 55.0% | 40 | 50.0% | 0.627 |
| Cranial nerves disorder | 35 | 43.8% | 29 | 36.3% | 32 | 40.0% | 0.532 |
| Consciousness disturbances | 14 | 17.5% | 11 | 13.8% | 21 | 26.3% | 0.120 |
| Aphasia | 19 | 23.8% | 17 | 21.3% | 18 | 22.5% | 0.931 |
| Sensation disorders | 11 | 13.8% | 15 | 18.8% | 14 | 17.5% | 0.677 |
| Vertigo | 22 | 27.5% | 9 | 11.3% | 13 | 16.3% | 0.025 |
| Headache | 6 | 7.5% | 6 | 7.5% | 5 | 6.3% | 0.939 |
| Visual field disturbances | 5 | 6.3% | 2 | 2.5% | 3 | 3.8% | 0.614 |
| Ataxia | 3 | 3.8% | 8 | 10.0% | 2 | 2.5% | 0.156 |
| Monocular vision | 3 | 3.8% | 2 | 2.5% | 0 | 0.0% | 0.376 |
Frequency of comorbidities.
| VAH | SVAA | Control |
| ||||
|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | ||
| Hypertension | 54 | 67.5% | 44 | 55.0% | 59 | 73.8% | 0.040 |
| Artherosclerosis | 38 | 47.5% | 46 | 57.5% | 36 | 45.0% | 0.247 |
| Diabetes | 18 | 22.5% | 14 | 17.5% | 20 | 25.0% | 0.503 |
| Atrial fibrillation | 14 | 17.5% | 6 | 7.5% | 14 | 17.5% | 0.112 |
| Heart failure | 11 | 13.8% | 12 | 15.0% | 9 | 11.3% | 0.777 |
Cerebral imaging findings.
| Type o Brain Lesions | VAH | SVAA | Control Group |
| |||
|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | ||
| Supratentorial ischemic lesions | 54 | 67.5% | 62 | 77.5% | 56 | 70.0% | 0.344 |
| Brainstem ischemic lesions | 3 | 3.8% | 3 | 3.8% | 1 | 1.3% | 0.555 |
| Cerebellum ischemic lesions | 8 | 10.0% | 13 | 16.3% | 4 | 5.0% | 0.075 |
Outcome of hospitalization.
| Outcome of Hospitalization | VAH | SVAA | Control |
| |||
|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | ||
| Deterioration | 4 | 5.0% | 3 | 3.8% | 4 | 5.0% | 0.981 |
| Recovery | 52 | 65.0% | 51 | 63.8% | 53 | 66.3% | |
| Stable | 24 | 30.0% | 26 | 32.5% | 23 | 28.8% | |